MedTrace Logo

Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer

NCT04799639 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-06-25

No results posted yet for this study

Summary

To determine the safety and efficacy of Sindilimab combined with Paclitaxel and Cisplatin in neoadjuvant chemotherapy for Locally Advanced Cervical Cancer

Conditions

  • Cervical Cancer
  • Chemotherapy Effect
  • Programmed Cell Death 1 Receptor / Antagonists & Inhibitors
  • Neoadjuvant Therapy

Interventions

DRUG

Sindilimab +paclitaxel+ cisplantin

standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Jihong Liu, Ph.D. · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2024-06-17
Completion
2024-06-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04799639 on ClinicalTrials.gov